TFX Teleflex Incorporated

Teleflex Incorporated Announces Global Recall of Rüsch Endotracheal Tubes

Teleflex Incorporated Announces Global Recall of Rüsch Endotracheal Tubes

WAYNE, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a global recall of affected batches of the below-mentioned Rüsch Endotracheal Tube products. The Rüsch Endotracheal Tube devices are indicated for oral or nasal intubation for airway management via insertion into a patient’s tracheal via nose or mouth. Stylets are used to aid insertion of endotracheal tubes into the trachea.

The products involved in the recall are as follows. Additional detail about how to identify the affected products is available in the .

Type of ActionRecall Notice
Teleflex ReferenceEIF-000537
Product Code & Batch/Lot NumberRefer to Appendix 2 of the recall notice
Commercial Name
TOP Endotracheal tube with CuffRUSCHELIT® Preformed Nasal Tracheal Tube, Two Eyes without Cuff
Slick Set ® Cuffed Endotracheal Tube and Stylet Set, oral/nasalRUSCHELIT® Safety Clear Tracheal Tube, oral/nasal
Slick Set ® Uncuffed Endotracheal Tube and Stylet Set, oral/nasalSafety Clear Tracheal tube (without Cuff)
Flexi-Set Cuffed Endotracheal Tube and Stylet Set, oral/nasalRUSCHELIT® Preformed Oral Tracheal Tube, Cuffed, Oral, Murphy Eye
Flexi-Set Uncuffed Endotracheal Tube and Stylet Set, oral/nasalAGT Orotracheal tube
Preformed AGT Oral Endotracheal Tube uncuffed/plain - MurphyRUSCHELIT® Preformed Nasal Tracheal Tube, Cuffed, Nasal, Murphy Eye
Preformed AGT Nasal Endotracheal Tube uncuffed/plain - MurphyAGT Nasotracheal tube
Endotracheal Tube oral/nasal uncuffed/plain - MurphyRUSCHELIT® Safety Clear Plus Tracheal Tube, oral/nasal, Cuffed
Preformed AGT Oral Endotracheal Tube Murphy Eye, High Volume, Low Pressure CuffRUSCHELIT® Super Safety Clear Microlaryngeal Tube, oral/nasal
Preformed AGT Nasal Endotracheal Tube Murphy Eye, High Volume, Low Pressure CuffRUSCHELIT® Super Safety Clear Tracheal Tube, oral/nasal, Cuffed
Endotracheal Tube oral/nasal Magill, High Volume, Low Pressure CuffFlexiset Super Safety Clear Tracheal Tube, oral/nasal with Cuff and Insertion Aid
Endotracheal Tube oral/nasal Murphy Eye, High Volume, Low Pressure CuffRUSCHELIT ® Safety Clear Tracheal Tube, oral/nasal, Murphy
RUSCHELIT ® Safety Clear Tracheal Tube, oral/nasal, MagillSuper Safety Clear Tracheal tube
RUSCHELIT® Preformed Oral Tracheal Tube, Two Eyes without CuffENDOSOFT Tracheal tube
Endotracheal Tube oral/nasal uncuffed/plain – MagillRUSCHELIT® Edgar Tube (no cuff)
RUSCHELIT® Edgar Tube (cuffed) 
Note: This recall is for specific lots / batches of the above product codes manufactured prior to April 24th, 2023



Teleflex commenced this voluntary Field Safety Corrective Action on May 23, 2023 due to reports of disconnection of the 15mm connector from the endotracheal tube (ET tube) for the affected products. There is the possibility of oxygen desaturation and in that event any immediate or long-term health consequences are dependent on the degree and duration of desaturation. All batches of Rüsch Endotracheal Tubes as listed in table above, manufactured between JAN2018 to 24APR2023 are subject to this recall. Reference Appendix 2 of the for a full list of affected lots / batches.

Where patients are undergoing mechanical ventilation in either the operating room or critical care settings, the ventilation devices to which the affected products are connected are designed to alarm immediately upon a disconnection in the breathing circuit, alerting the clinician to reattach the connector. Additional standards of care such as pulse oximetry also alert clinicians to desaturation within seconds of its occurrence, again permitting prompt reattachment of the connector.

As of 15-June-2023, Teleflex received 189 complaints reporting connector issues for products in scope of this field correction. Of these 189 complaints, 11 reported injury, including nine reports of patient desaturation, and four reports of patient death. Three complaints reported that the patient deaths were unrelated to the disconnection of the device and one complaint reported that it was impossible to determine whether the device contributed to the patient death.

The initial investigation has identified that the disconnection results from intermittent cross-contamination of the 15mm connector with trace amounts of silicone oil. Although this does increase the lubricity of the connection, this does not present additional clinical risks.

For product in situ, Teleflex advises clinical staff to ensure the 15 mm connector is seated firmly in the ET tube to prevent disconnection during use per the product instructions for use. Should disconnection occur, reconnect the two components promptly and securely in the manner described in the product instructions for use. Clinical staff may wish to consider replacing the device, making sure to evaluate on a case by case basis the risks associated with extubation and reintubation.

The recall notice, with a list of affected product codes and lot numbers, can be found through the following link:

Consumers with questions may contact the company at 1-866-396-2111; 8am to 7pm, ET, Monday through Friday or email .

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: , or via Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Arrow-Trerotola, Deknatel, LMA, Pilling, PTD, QuikClot, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

Source:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development



610-948-2836

 



EN
21/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhex...

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guin...

 PRESS RELEASE

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Thro...

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and th...

 PRESS RELEASE

Teleflex Publishes 2024 Global Impact Report

Teleflex Publishes 2024 Global Impact Report Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Cl...

 PRESS RELEASE

Teleflex Showcases New Clinical Data Presented at the 2025 American Ur...

Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 ...

 PRESS RELEASE

New Retrospective Study Reports Significantly Reduced Post-Operative G...

New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading g...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch